Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of dyslipidemia in diabetes
Autore:
Garber, AJ; Karlsson, FO;
Indirizzi:
Baylor Coll Med, Dept Med, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 Med, Dept Med, Houston, TX 77030 USA Baylor Coll Med, Dept Biochem & Cell Biol, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 m & Cell Biol, Houston, TX 77030 USA Baylor Coll Med, Dept Family & Community, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 y & Community, Houston, TX 77030 USA Methodist Hosp, Dept Diabet Endocrinol & Metab, Houston, TX 77030 USA Methodist Hosp Houston TX USA 77030 crinol & Metab, Houston, TX 77030 USA
Titolo Testata:
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
fascicolo: 4, volume: 30, anno: 2001,
pagine: 999 -
SICI:
0889-8529(200112)30:4<999:TODID>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; HEALTH-CARE PROFESSIONALS; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; RISK-FACTORS; THERAPY; MEN; TRIAL; HYPERTRIGLYCERIDEMIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Garber, AJ Baylor Coll Med, Dept Med, 6550 Fannin St,Suite 1045, Houston, TX 77030 USA Baylor Coll Med 6550 Fannin St,Suite 1045 Houston TX USA 77030
Citazione:
A.J. Garber e F.O. Karlsson, "Treatment of dyslipidemia in diabetes", END METAB C, 30(4), 2001, pp. 999

Abstract

Atherosclerosis kills more patients with diabetes than all other causes combined. Treatment must be focused on several targets: glycemic control, bulk reductions of LDL cholesterol, and shifting LDL particle size. Aggressivetreatment and reversal of dyslipidemias is a proven prevention for coronary events in patients with type 2 diabetes. Glycemic control with diet, oralhypoglycemic agents, and insulin, when necessary, often is only partially effective in normalizing lipid values in type 2 diabetes. Intensive treatment with lipid-regulating agents, particularly statins, often is necessary to normalize diabetes-associated dyslipidemias. Statins also are the only agents thus far shown in prospective, controlled trials to reduce the risk ofcoronary events in diabetic patients definitively.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 14:32:34